23andMe's stock, which hit a $6B valuation after a 2021 IPO, has crashed 98% and 23andMe may run out of cash by 2025, as CEO Anne Wojcicki plots a turnaround (Rolfe Winkler/Wall Street Journal)

Rolfe Winkler / Wall Street Journal:

23andMe’s stock, which hit a $6B valuation after a 2021 IPO, has crashed 98% and 23andMe may run out of cash by 2025, as CEO Anne Wojcicki plots a turnaround  —  From celebrity ‘spit parties’ to a drop in the bucket: The once-hot DNA-testing company is struggling to profit